GlassScriptPhysician profile
Lawrence B Grossman
NPI 1477618270
$7,678.21
in general payments reported to CMS, 2019-2025
30 companies · $183 in 2025
The $183 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,192 · 2020: $1,362 · 2021: $2,247 · 2022: $772 · 2023: $850 · 2024: $71.69 · 2025: $183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,082 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,081.95 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,775.05 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,371.32 | 2019-2025 | Xifaxan |
| Gilead Sciences, INC. | $848.04 | 2019-2023 | Vemlidy |
| Janssen Biotech, INC. | $737.29 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $552.48 | 2019-2025 | Gattex, Eohilia |
| Merck Sharp & Dohme LLC | $384.84 | 2019-2023 | Dificid |
| Pfizer INC. | $255.79 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $227.57 | 2020-2021 | |
| Ironwood Pharmaceuticals, INC | $226.99 | 2019-2021 | |
| Redhill Biopharma INC. | $157.08 | 2020-2021 | |
| Celgene Corporation | $141.57 | 2021-2023 | Zeposia |
| Intercept Pharmaceuticals, INC. | $131.64 | 2019-2021 | |
| Ucb, INC. | $115.83 | 2019-2021 | |
| Braintree Laboratories, INC. | $113.49 | 2019-2021 | |
| Qol Medical, LLC | $95.94 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $92.93 | 2019 | |
| Evoke Pharma, INC. | $60.73 | 2021 | |
| Shionogi INC | $44.97 | 2019 | |
| Pharmacosmos Therapeutics INC. | $44.46 | 2021 | |
| Ferring Pharmaceuticals INC. | $43.92 | 2019-2021 | |
| Concordia Pharmaceuticals INC. | $43.36 | 2019 | |
| Allergan, INC. | $41.83 | 2019 | |
| Mauna Kea Technologies, INC. | $31.03 | 2020-2021 | |
| Genzyme Corporation | $27.06 | 2025 | |
| Daiichi Sankyo INC. | $23.22 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $22.16 | 2024 | Dupixent |
| Axonics, INC. | $21.28 | 2021 | |
| Alnylam Pharmaceuticals INC. | $18.22 | 2022 | |
| Dova Pharmaceuticals | $14.70 | 2019 | |
| Capsovision, INC. | $13.42 | 2023 | Capsocam Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Grossman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.